Pular para o conteúdo principal
Ranking Invest

ACRS - Aclaris Therapeutics, Inc.

Segmento: HealthcareAclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Análise Ranking Invest

Valuation estimado
-8,59%
-$ 219.94 Mi
Valor de Mercado
$ 782.36 Mi
Desconto (AV)-455.7%
IVR
-0.28A companhia vale -0,28 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.44O valuation alternativo equivale a -44% do valor de mercado da companhia.
MLL
-0.44O lucro líquido dos controladores em 16 trimestres equivale a -44% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 124.58 Mi

Dívida Líquida

-$ 19.17 Mi

L4T

-$ 75.74 Mi

MM4T

-1071.22%

Indicadores Básicos

ROE

-60.79%

Índices de Previsibilidade

Receita Líquida

F0.67

Lucro

C0.34

Margem

C0.52

Índices de Tendência

Receita Líquida

E-6.62

Lucro

B4.63

Margem

F-5.10

Índices de Endividamento

DIV/PAT

-0.15

DIV/L4T

0.25

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.